Evaluation of a New Pediatric Positive Airway Pressure Mask

Kushida, Clete A.; Halbower, Ann C.; Kryger, Meir H.; Pelayo, Rafael; Assalone, Valerie; Cardell, Chia Yu; Huston, Stephanie; Willes, Leslee; Wimms, Alison; Mendoza, June

doi:10.5664/jcsm.4030

Cited by 9 publications

(6 citation statements)

References 19 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Children with OSA who cannot tolerate the CPAP masks may benefit from HFNC treatment [74]. Pediatric OSA has been successfully treated with high-flow heated, humidified nasal air [28,[75][76][77].…”

Section: High-flow Nasal Cannula Therapymentioning

confidence: 99%

Medical Treatment of Obstructive Sleep Apnea in Children

Ergenekon,

Gokdemir,

Ersu

2023

JCM

View full text Add to dashboard Cite

Obstructive sleep apnea (OSA) is characterized by recurrent complete or partial obstruction of the upper airway. The prevalence is 1–4% in children aged between 2 and 8 years and rising due to the increase in obesity rates in children. Although persistent OSA following adenotonsillectomy is usually associated with obesity and underlying complex disorders, it can also affect otherwise healthy children. Medical treatment strategies are frequently required when adenotonsillectomy is not indicated in children with OSA or if OSA is persistent following adenotonsillectomy. Positive airway pressure treatment is a very effective modality for persistent OSA in childhood; however, adherence rates are low. The aim of this review article is to summarize medical treatment options for OSA in children.

show abstract

Section: High-flow Nasal Cannula Therapymentioning

confidence: 99%

Medical Treatment of Obstructive Sleep Apnea in Children

Ergenekon,

Gokdemir,

Ersu

2023

JCM

View full text Add to dashboard Cite

show abstract

“…Nasal masks are the most used interface [86,141,[153][154][155][156] with an adequate fitting of the interface having shown to be crucial for CPAP/NIV success [86,141,156,157]. It may be difficult to find a well-fitted interface for children with facial deformity [141,154].…”

Section: And 42)mentioning

confidence: 99%

ERS statement on paediatric long-term noninvasive respiratory support

et al. 2021

View full text Add to dashboard Cite

Long term noninvasive respiratory support, comprising continuous positive airway pressure (CPAP) and noninvasive ventilation (NIV), in children is expanding worldwide, with increasing complexities of children being considered for this type of ventilator support and expanding indications such as palliative care. There have been improvements in equipment and interfaces. Despite growing experience, there are still gaps in a significant number of areas: there is a lack of validated criteria for CPAP/NIV initiation, optimal follow-up and monitoring; weaning and long term benefits have not been evaluated. Therapeutic education of the caregivers and the patient is of paramount importance, as well as continuous support and assistance, in order to achieve optimal adherence. The preservation or improvement of the quality of life of the patient and caregivers should be a concern for all children treated with long term CPAP/NIV. As NIV is a highly specialised treatment, patients are usually managed by an experienced pediatric multidisciplinary team. This Statement written by experts in the field of pediatric long term CPAP/NIV aims to emphasize on the most recent scientific input and should open up to new perspectives and research areas.

show abstract

“…Use of different interfaces may also help improve the challenges with adherence. Kushida et al compared a new mask interface (Pixi® mask) with the patients’ old one in children aged 2–7 years. There was no difference in the AHI between the two interfaces and parents rated the Pixi mask positively for restfulness of the child's sleep and trouble in getting the child to sleep or having the child stay asleep.…”

Section: Treatment Affecting the Entire Upper Airway: Cpap And Nppvmentioning

confidence: 99%

Adenotonsillectomy to treat obstructive sleep apnea: Is it enough?

Boudewyns

Abel

Alexopoulos

et al. 2017

Pediatric Pulmonology

View full text Add to dashboard Cite

Although adenotonsillectomy is the first line treatment for children with obstructive sleep apnea syndrome (0SAS), improvement in objectively documented outcomes is often inadequate and a substantial number of children have residual disease. Early recognition and treatment of children with persistent OSAS is required to prevent long-term morbidity. The management of these children is frequently complex and a multidisciplinary approach is required as most of them have additional risk factors for OSAS and comorbidities. In this paper, we first provide an overview of children at risk for persistent disease following adenotonsillectomy. Thereafter, we discuss different diagnostic modalities to evaluate the sites of persistent upper airway obstruction and the currently available treatment options. Pediatr Pulmonol. 2017;52:699-709. © 2016 Wiley Periodicals, Inc.

show abstract

Evaluation of a New Pediatric Positive Airway Pressure Mask

Abstract: The Pixi mask is suitable for children aged 2-7 years and provides an alternative to other masks available for PAP therapy in this age group.

Cited by 9 publications

References 19 publications

Medical Treatment of Obstructive Sleep Apnea in Children

Medical Treatment of Obstructive Sleep Apnea in Children

ERS statement on paediatric long-term noninvasive respiratory support

Adenotonsillectomy to treat obstructive sleep apnea: Is it enough?

Contact Info

Product

Resources

About